Current Report Filing (8-k)
December 28 2018 - 5:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 28, 2018
ACTINIUM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
000-52446
|
|
74-2963609
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
275 Madison Avenue, 7th Floor
New York, NY
|
|
10016
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code:
(646) 677-3870
N/A
|
(Former name or former address, if changed since last report)
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a -12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d -2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e -4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 1.01
Entry
into a Material Definitive Agreement
On December 28, 2018, Actinium
Pharmaceuticals, Inc. (the “Company”) entered into an Amended and Restated At Market Issuance Sales Agreement (the
“Amended Agreement”) with B. Riley FBR, Inc. (“B. Riley FBR”) and JonesTrading Institutional Services LLC
(“JonesTrading”). Pursuant to the Amended Agreement, JonesTrading was added as an agent to the original At Market Issuance
Sales Agreement, dated March 16, 2017 with B. Riley FBR, as successor by merger to FBR Capital Markets & Co. Subject to the
terms and conditions of the Amended Agreement, the agents will use commercially reasonable efforts to sell the Company’s
common stock from time to time, based upon the Company’s instructions (including any price, time or size limits or other
customary parameters or conditions the Company may impose). The Company will pay to the agents in cash, upon the sale of common
stock pursuant to the Amended Agreement, an amount equal to 3.0% of the gross proceeds from the sale of common stock. A
copy of the Amended Agreement will be included as an exhibit to the Company’s Form 10-K for the year ending December 31,
2018.
Dated: December 28, 2018
|
ACTINIUM PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/ Sandesh Seth
|
|
Name:
|
Sandesh Seth
|
|
Title:
|
CEO & Chairman
|
2
Actinium Pharmaceuticals (AMEX:ATNM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Actinium Pharmaceuticals (AMEX:ATNM)
Historical Stock Chart
From Sep 2023 to Sep 2024